3,4-dihydroxyphenylacetic acid has been researched along with MPTP Neurotoxicity Syndrome in 116 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trichostatin A (TSA) was further used to study the effects of histone deacetylase inhibition on NRSF-mediated repression." | 1.42 | NRSF is an essential mediator for the neuroprotection of trichostatin A in the MPTP mouse model of Parkinson's disease. ( Cai, L; Fei, J; Huang, D; Huang, F; Huang, L; Huang, Y; Liu, J; Ma, Y; Suo, H; Tong, J; Wang, P; Wang, Z; Xu, J; Yu, M, 2015) |
| "A goldfish (Carassius auratus) model of Parkinson's disease (PD) was constructed by a single dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) according to previously reported methods." | 1.40 | (1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Kong, L; Li, M; Liu, Q; Lu, Z; Wang, J; Wei, D; Yang, M, 2014) |
| "3% of the administered dose was taken up by the brain and was slowly eliminated, with a half-life of approximately 3 weeks." | 1.39 | Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice. ( Beck, M; Botham, PA; Breckenridge, CB; Butt, M; Cook, AR; Mathews, JM; Minnema, D; Smith, LL; Sturgess, NC; Tisdel, MO; Travis, KZ; Wolf, JC; Zadory, D, 2013) |
| "Rotenone was injected into MPTP-treated mice over a period of 4 weeks." | 1.36 | Chronic administration with rotenone does not enhance MPTP neurotoxicity in C57BL/6 mice. ( Aoki, E; Araki, T; Kato, H; Kimoto, H; Yano, R; Yokoyama, H, 2010) |
| "Zonisamide treatment alone did not produce any lasting effects on ex vivo MAO-B activity, indicating that it is a reversible inhibitor of the enzyme." | 1.36 | The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. ( Buckley, B; Sonsalla, PK; Winnik, B; Wong, LY, 2010) |
| "Rosiglitazone is a commonly prescribed insulin-sensitizing drug with a selective agonistic activity on the peroxisome proliferator-activated receptor-gamma (PPAR-gamma)." | 1.35 | PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. ( Caboni, P; Carboni, E; Carta, AR; Frau, L; Garau, A; Ibba, M; Schintu, N, 2009) |
| " We thus observed the influence of deficiency of complement 3 (C3), the key component of complement system, on the death of dopaminergic neurons in substantia nigra pars compacta (SNpc) and the loss of dopaminergic fibers in striatum induced by acute or chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.34 | Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity. ( Guo, Q; Li, S; Liang, Y; Su, B; Wen, C; Zhang, Y; Zou, Q, 2007) |
| "The psychostimulant methamphetamine (MA) is toxic to nigro-striatal dopaminergic terminals in both experimental animals and humans." | 1.32 | Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. ( Battaglia, G; Busceti, CL; De Blasi, A; Fornai, F; Lembo, G; Nicoletti, F, 2003) |
| " Protection was more profound with an acute dosing regimen than with daily MPTP administration over 5 d." | 1.30 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. ( Beal, MF; Hyman, BT; Klockgether, T; Liao, AW; Martinou, JC; Matthews, RT; Penney, JB; Schulz, JB; Yang, L, 1998) |
| " Recent evidence has demonstrated that chronic administration of MPTP can lead to apoptotic cell death." | 1.30 | Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. ( Andreassen, O; Beal, MF; Ferrante, RJ; Friedlander, RM; Klevenyi, P; Schleicher, JR, 1999) |
| "The behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset." | 1.29 | Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. ( Albanese, A; Colosimo, C; Granata, R; Gregori, B; Piccardi, MP; Tonali, P, 1993) |
| "Effects of acute and chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were investigated for dopamine (DA) and its metabolites, 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid, in nucleus caudatus putamen (NCP), limbic system, and substantia nigra (SN) of golden hamster and BALB/c and C57/BL mice to obtain a clue for the variance of MPTP toxicity between the strains and species." | 1.29 | Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase B. ( Ganguly, DK; Mitra, N; Mohanakumar, KP, 1994) |
| " MPTP produced a slight but significant decrease of DA only 4 hours post dosing on PND 23." | 1.29 | Age-related susceptibility to MPTP-induced neurotoxicity in mice. ( Ali, SF; David, SN; Newport, GD, 1993) |
| " The results suggest that the selected dosage schedule produces a widespread and lasting neuronal degeneration closely resembling the neurochemical pathology of Parkinson's disease." | 1.28 | Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. ( De Ceballos, ML; Del Río, J; Herrero, MT; Luquin, MR; Obeso, JA; Oset, C; Pérez-Otaño, I, 1991) |
| "Treatment with bromocriptine (5 mg/kg) relieved the parkinsonian symptoms, but the efficacy of this treatment appeared to decrease slightly with time." | 1.28 | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. ( Bédard, PJ; Di Paolo, T; Rouillard, C, 1990) |
| " It is proposed that the retinal dopaminergic system is less sensitive to the toxic effects of MPTP than the nigro-striatal pathway." | 1.28 | Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence. ( Di Paolo, T; Harnois, C; Marcotte, G, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.72) | 18.7374 |
| 1990's | 41 (35.34) | 18.2507 |
| 2000's | 37 (31.90) | 29.6817 |
| 2010's | 36 (31.03) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moreno-Galarza, N | 1 |
| Mendieta, L | 1 |
| Palafox-Sánchez, V | 1 |
| Herrando-Grabulosa, M | 1 |
| Gil, C | 1 |
| Limón, DI | 1 |
| Aguilera, J | 1 |
| Pavshintsev, VV | 1 |
| Podshivalova, LS | 1 |
| Frolova, OY | 1 |
| Belopolskaya, MV | 1 |
| Averina, OA | 1 |
| Kushnir, EA | 1 |
| Marmiy, NV | 1 |
| Lovat, ML | 1 |
| Bhurtel, S | 1 |
| Katila, N | 1 |
| Srivastav, S | 1 |
| Neupane, S | 1 |
| Choi, DY | 2 |
| Breckenridge, CB | 1 |
| Sturgess, NC | 1 |
| Butt, M | 1 |
| Wolf, JC | 1 |
| Zadory, D | 1 |
| Beck, M | 1 |
| Mathews, JM | 1 |
| Tisdel, MO | 1 |
| Minnema, D | 1 |
| Travis, KZ | 1 |
| Cook, AR | 1 |
| Botham, PA | 1 |
| Smith, LL | 1 |
| Jones, BC | 2 |
| Miller, DB | 2 |
| O'Callaghan, JP | 2 |
| Lu, L | 2 |
| Unger, EL | 1 |
| Alam, G | 2 |
| Williams, RW | 2 |
| Sai, T | 1 |
| Uchida, K | 1 |
| Nakayama, H | 1 |
| Rekha, KR | 1 |
| Selvakumar, GP | 1 |
| Santha, K | 1 |
| Inmozhi Sivakamasundari, R | 1 |
| Miao, SH | 1 |
| Sun, HB | 1 |
| Ye, Y | 1 |
| Yang, JJ | 1 |
| Shi, YW | 1 |
| Lu, M | 1 |
| Hu, G | 1 |
| Zhou, JW | 1 |
| Chen, T | 1 |
| Hou, R | 1 |
| Li, C | 1 |
| Wu, C | 1 |
| Xu, S | 1 |
| Lu, Z | 1 |
| Wang, J | 1 |
| Li, M | 1 |
| Liu, Q | 1 |
| Wei, D | 1 |
| Yang, M | 1 |
| Kong, L | 1 |
| Benskey, MJ | 1 |
| Manfredsson, FP | 1 |
| Lookingland, KJ | 1 |
| Goudreau, JL | 1 |
| Litim, N | 1 |
| Bourque, M | 1 |
| Al Sweidi, S | 2 |
| Morissette, M | 6 |
| Di Paolo, T | 7 |
| Mounsey, RB | 1 |
| Martin, HL | 2 |
| Nelson, MC | 1 |
| Evans, RM | 1 |
| Teismann, P | 2 |
| Suo, H | 1 |
| Wang, P | 1 |
| Tong, J | 1 |
| Cai, L | 1 |
| Liu, J | 1 |
| Huang, D | 1 |
| Huang, L | 1 |
| Wang, Z | 1 |
| Huang, Y | 1 |
| Xu, J | 1 |
| Ma, Y | 1 |
| Yu, M | 1 |
| Fei, J | 1 |
| Huang, F | 1 |
| Zhou, JJ | 1 |
| Zhai, SY | 1 |
| Zhang, HN | 1 |
| Wang, YH | 1 |
| Pu, XP | 1 |
| Santoro, M | 1 |
| Mustafa, S | 1 |
| Riedel, G | 1 |
| Forrester, JV | 1 |
| Kim, AR | 1 |
| Ugryumov, MV | 1 |
| Moraes, LS | 1 |
| Rohor, BZ | 1 |
| Areal, LB | 2 |
| Pereira, EV | 1 |
| Santos, AM | 1 |
| Facundo, VA | 1 |
| Santos, AR | 1 |
| Pires, RG | 2 |
| Martins-Silva, C | 2 |
| Klein, C | 1 |
| Rasińska, J | 1 |
| Empl, L | 1 |
| Sparenberg, M | 1 |
| Poshtiban, A | 1 |
| Hain, EG | 1 |
| Iggena, D | 1 |
| Rivalan, M | 1 |
| Winter, Y | 1 |
| Steiner, B | 1 |
| Hilario, WF | 1 |
| Herlinger, AL | 1 |
| de Moraes, LS | 1 |
| Ferreira, TA | 1 |
| Andrade, TE | 1 |
| Torok, R | 1 |
| Salamon, A | 1 |
| Sumegi, E | 1 |
| Zadori, D | 1 |
| Veres, G | 1 |
| Molnar, MF | 1 |
| Vecsei, L | 1 |
| Klivenyi, P | 5 |
| Yokoyama, H | 4 |
| Yano, R | 2 |
| Aoki, E | 2 |
| Kato, H | 6 |
| Araki, T | 7 |
| Ookubo, M | 2 |
| Takagi, S | 1 |
| Minematsu, M | 1 |
| Nakajima, K | 1 |
| Schintu, N | 1 |
| Frau, L | 1 |
| Ibba, M | 1 |
| Caboni, P | 1 |
| Garau, A | 1 |
| Carboni, E | 1 |
| Carta, AR | 1 |
| Joniec, I | 1 |
| Ciesielska, A | 1 |
| Kurkowska-Jastrzebska, I | 1 |
| Przybylkowski, A | 1 |
| Czlonkowska, A | 1 |
| Czlonkowski, A | 1 |
| Luo, D | 1 |
| Zhang, Q | 1 |
| Wang, H | 1 |
| Cui, Y | 1 |
| Sun, Z | 1 |
| Yang, J | 1 |
| Zheng, Y | 1 |
| Jia, J | 1 |
| Yu, F | 1 |
| Wang, X | 2 |
| Gal, S | 1 |
| Zheng, H | 1 |
| Fridkin, M | 1 |
| Youdim, MB | 1 |
| Kimoto, H | 1 |
| Han, B | 1 |
| Zhao, H | 1 |
| Sonsalla, PK | 3 |
| Wong, LY | 1 |
| Winnik, B | 1 |
| Buckley, B | 1 |
| Li, XM | 1 |
| Ma, HB | 1 |
| Ma, ZQ | 1 |
| Li, LF | 1 |
| Xu, CL | 1 |
| Qu, R | 1 |
| Ma, SP | 1 |
| Khan, HA | 1 |
| Gao, L | 1 |
| Díaz-Martín, J | 1 |
| Dillmann, WH | 1 |
| López-Barneo, J | 1 |
| Tsai, SJ | 1 |
| Chao, CY | 1 |
| Yin, MC | 1 |
| Drouin-Ouellet, J | 1 |
| Gibrat, C | 1 |
| Bousquet, M | 1 |
| Calon, F | 1 |
| Kriz, J | 1 |
| Cicchetti, F | 1 |
| Schumm, S | 1 |
| Sebban, C | 1 |
| Cohen-Salmon, C | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Golmard, JL | 1 |
| Boussicault, L | 1 |
| Petropoulos, I | 1 |
| Hild, A | 1 |
| Rousselet, E | 1 |
| Prigent, A | 1 |
| Friguet, B | 1 |
| Mariani, J | 1 |
| Hirsch, EC | 1 |
| Lee, MK | 1 |
| Hong, JT | 1 |
| Dhanushkodi, A | 1 |
| Akano, EO | 1 |
| Roguski, EE | 1 |
| Xue, Y | 1 |
| Rao, SK | 1 |
| Matta, SG | 1 |
| Rex, TS | 1 |
| McDonald, MP | 1 |
| Dodd, CA | 1 |
| Bloomquist, JR | 1 |
| Klein, BG | 1 |
| Crabtree, D | 1 |
| Boyer-Guittaut, M | 1 |
| Ouyang, X | 1 |
| Fineberg, N | 1 |
| Zhang, J | 1 |
| Ekue, A | 1 |
| Boulanger, JF | 1 |
| Schlüter, OM | 1 |
| Fornai, F | 4 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| Vaglini, F | 2 |
| Pardini, C | 1 |
| Bonuccelli, U | 2 |
| Maggio, R | 2 |
| Corsini, GU | 2 |
| Battaglia, G | 2 |
| Busceti, CL | 2 |
| Lembo, G | 1 |
| Nicoletti, F | 2 |
| De Blasi, A | 1 |
| Obuchowicz, E | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Romańska, I | 1 |
| Herman, ZS | 1 |
| Molinaro, G | 1 |
| Biagioni, F | 1 |
| Storto, M | 1 |
| Bruno, V | 1 |
| Watanabe, H | 1 |
| Muramatsu, Y | 1 |
| Kurosaki, R | 2 |
| Michimata, M | 1 |
| Matsubara, M | 1 |
| Imai, Y | 1 |
| Calingasan, NY | 3 |
| Starkov, A | 1 |
| Stavrovskaya, IG | 1 |
| Kristal, BS | 1 |
| Yang, L | 4 |
| Wieringa, B | 1 |
| Beal, MF | 7 |
| Aubin, N | 1 |
| Barneoud, P | 1 |
| Carter, C | 1 |
| Caille, D | 1 |
| Sontag, N | 1 |
| Marc, C | 1 |
| Lolivier, J | 1 |
| Gardes, A | 1 |
| Perron, C | 1 |
| Le Kim, A | 1 |
| Charieras, T | 1 |
| Pandini, M | 1 |
| Burnier, P | 1 |
| Puech, F | 1 |
| Jegham, S | 1 |
| George, P | 1 |
| Scatton, B | 1 |
| Curet, O | 1 |
| Oki, C | 1 |
| Rommelfanger, KS | 1 |
| Weinshenker, D | 1 |
| Miller, GW | 1 |
| Shen, YQ | 1 |
| Hebert, G | 1 |
| Lin, LY | 1 |
| Luo, YL | 1 |
| Moze, E | 1 |
| Li, KS | 1 |
| Neveu, PJ | 1 |
| D'Astous, M | 1 |
| Callier, S | 2 |
| Shimoji, M | 1 |
| Zhang, L | 1 |
| Mandir, AS | 1 |
| Dawson, VL | 2 |
| Dawson, TM | 2 |
| Gardian, G | 1 |
| von Borstel, R | 1 |
| Saydoff, J | 1 |
| Browne, SE | 1 |
| Shepherd, KR | 1 |
| Lee, ES | 1 |
| Schmued, L | 1 |
| Jiao, Y | 1 |
| Ali, SF | 5 |
| Oriaku, ET | 1 |
| Lamango, NS | 1 |
| Soliman, KF | 1 |
| Charlton, CG | 1 |
| Mohanasundari, M | 1 |
| Srinivasan, MS | 1 |
| Sethupathy, S | 1 |
| Sabesan, M | 1 |
| Jourdain, S | 1 |
| Menniti, FS | 1 |
| Ramirez, AD | 1 |
| Liang, Y | 1 |
| Li, S | 1 |
| Guo, Q | 1 |
| Zhang, Y | 2 |
| Wen, C | 1 |
| Zou, Q | 1 |
| Su, B | 1 |
| Watanabe, Y | 1 |
| Lorenzo, BJ | 1 |
| Blanchet, J | 1 |
| Longpré, F | 1 |
| Bureau, G | 1 |
| DiPaolo, T | 1 |
| Bronchti, G | 1 |
| Martinoli, MG | 1 |
| Pérez-Otaño, I | 3 |
| Luquin, MR | 3 |
| Oset, C | 3 |
| Herrero, MT | 3 |
| Kupsch, A | 1 |
| Oertel, W | 1 |
| Obeso, JA | 3 |
| Del Río, J | 3 |
| Fascetti, F | 1 |
| Schneider, JS | 3 |
| DiStefano, L | 2 |
| David, SN | 2 |
| Newport, GD | 2 |
| Cadet, JL | 1 |
| Slikker, W | 1 |
| Desole, MS | 3 |
| Esposito, G | 2 |
| Fresu, L | 2 |
| Migheli, R | 2 |
| Enrico, P | 2 |
| Miele, M | 3 |
| De Natale, G | 2 |
| Miele, E | 3 |
| Hadjiconstantinou, M | 1 |
| Hubble, JP | 1 |
| Wemlinger, TA | 1 |
| Neff, NH | 1 |
| Muthane, U | 1 |
| Ramsay, KA | 1 |
| Jiang, H | 1 |
| Jackson-Lewis, V | 2 |
| Donaldson, D | 1 |
| Fernando, S | 1 |
| Ferreira, M | 1 |
| Przedborski, S | 3 |
| Giovanni, A | 2 |
| Sieber, BA | 1 |
| Heikkila, RE | 2 |
| Vizuete, ML | 1 |
| Steffen, V | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Albanese, A | 1 |
| Granata, R | 1 |
| Gregori, B | 1 |
| Piccardi, MP | 1 |
| Colosimo, C | 1 |
| Tonali, P | 1 |
| Oishi, T | 1 |
| Hasegawa, E | 1 |
| Murai, Y | 1 |
| Mitra, N | 1 |
| Mohanakumar, KP | 2 |
| Ganguly, DK | 1 |
| Grella, G | 1 |
| Rose, S | 1 |
| Nomoto, M | 1 |
| Jackson, EA | 1 |
| Gibb, WR | 1 |
| Jaehnig, P | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Dluzen, DE | 2 |
| McDermott, JL | 1 |
| Liu, B | 1 |
| Yokoyama, R | 1 |
| Shibata, T | 1 |
| Jin, BK | 1 |
| Iacovitti, L | 1 |
| Gainetdinov, RR | 1 |
| Fumagalli, F | 1 |
| Jones, SR | 1 |
| Caron, MG | 1 |
| Tanila, H | 1 |
| Björklund, M | 1 |
| Riekkinen, P | 1 |
| Mitsumoto, Y | 1 |
| Watanabe, A | 1 |
| Mori, A | 1 |
| Koga, N | 1 |
| Cheng, FC | 1 |
| Ni, DR | 1 |
| Wu, MC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Matthews, RT | 1 |
| Schulz, JB | 1 |
| Klockgether, T | 1 |
| Liao, AW | 1 |
| Martinou, JC | 1 |
| Penney, JB | 1 |
| Hyman, BT | 1 |
| Gerhardt, GA | 1 |
| Cass, WA | 1 |
| Huettl, P | 1 |
| Brock, S | 1 |
| Zhang, Z | 1 |
| Gash, DM | 1 |
| Klevenyi, P | 1 |
| Andreassen, O | 1 |
| Ferrante, RJ | 3 |
| Schleicher, JR | 1 |
| Friedlander, RM | 1 |
| Fillebeen, C | 1 |
| Mitchell, V | 1 |
| Dexter, D | 1 |
| Benaissa, M | 1 |
| Beauvillain, J | 1 |
| Spik, G | 1 |
| Pierce, A | 1 |
| Itzhak, Y | 1 |
| Martin, JL | 1 |
| Donovan, DM | 1 |
| Miner, LL | 1 |
| Perry, MP | 1 |
| Revay, RS | 1 |
| Sharpe, LG | 1 |
| Kostic, V | 1 |
| Philpot, RM | 1 |
| Kirstein, CL | 1 |
| Rothman, RB | 1 |
| Schindler, CW | 1 |
| Uhl, GR | 1 |
| Andreassen, OA | 2 |
| Dedeoglu, A | 1 |
| Mueller, G | 1 |
| Lancelot, E | 2 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Fabre, E | 1 |
| Monserrat, J | 1 |
| Herrero, A | 1 |
| Barja, G | 1 |
| Leret, ML | 1 |
| Muralikrishnan, D | 1 |
| Thomas, B | 1 |
| Reif, D | 1 |
| Grandbois, M | 1 |
| Bezard, E | 1 |
| Jaber, M | 1 |
| Gonon, F | 1 |
| Boireau, A | 1 |
| Bloch, B | 1 |
| Gross, CE | 1 |
| Mandavilli, BS | 1 |
| Van Houten, B | 1 |
| Mao, L | 1 |
| Lau, YS | 1 |
| Petroske, E | 1 |
| Wang, JQ | 1 |
| Serra, PA | 1 |
| Sciola, L | 1 |
| Delogu, MR | 1 |
| Spano, A | 1 |
| Monaco, G | 1 |
| Rocchitta, G | 1 |
| Fuxe, K | 1 |
| Janson, AM | 1 |
| Rosén, L | 1 |
| Finnman, UB | 1 |
| Tanganelli, S | 1 |
| Morari, M | 1 |
| Goldstein, M | 1 |
| Agnati, LF | 1 |
| Nilsson, K | 1 |
| Hallberg, A | 1 |
| Pileblad, E | 1 |
| Tunek, A | 1 |
| Russ, H | 1 |
| Mihatsch, W | 1 |
| Gerlach, M | 1 |
| Riederer, P | 1 |
| Przuntek, H | 1 |
| Garant, D | 1 |
| Fariello, R | 1 |
| De Ceballos, ML | 1 |
| Rouillard, C | 1 |
| Bédard, PJ | 1 |
| Carr, LA | 1 |
| Rowell, PP | 1 |
| Camps, M | 1 |
| Ambrosio, S | 1 |
| Ballarin, M | 1 |
| Reiriz, J | 1 |
| Blesa, R | 1 |
| Mahy, N | 1 |
| Harnois, C | 1 |
| Marcotte, G | 1 |
116 other studies available for 3,4-dihydroxyphenylacetic acid and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2018 |
Effects of Mitochondrial Antioxidant SkQ1 on Biochemical and Behavioral Parameters in a Parkinsonism Model in Mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Brain; Dihydroxyphenylalanine; Dopamine; Immu | 2017 |
Mechanistic comparison between MPTP and rotenone neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Brain; Dopamine; Male; Mice, Inbred C57BL; MPTP | 2019 |
Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; B | 2013 |
Systems analysis of genetic variation in MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Brain; Disease Models, Animal; Dopamine; Gene E | 2013 |
Biochemical evaluation of the neurotoxicity of MPTP and MPP⁺ in embryonic and newborn mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 2013 |
Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acyclic Monoterpenes; | 2013 |
Astrocytic JWA expression is essential to dopaminergic neuron survival in the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Carrier Proteins; Cell Line; Cell Survival; Dis | 2014 |
MPTP/MPP+ suppresses activation of protein C in Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Antigens, CD; Brain; Cells, Cu | 2015 |
(1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2014 |
The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 2015 |
The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-alpha Reductase Inhibitors; Animals; Corpus Striatum; Dihydrotesto | 2015 |
The effect of neuronal conditional knock-out of peroxisome proliferator-activated receptors in the MPTP mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chromatography, High Pressure Liquid; Dopamine; Dopa | 2015 |
NRSF is an essential mediator for the neuroprotection of trichostatin A in the MPTP mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cell Line, Tumor; Dopamine; Drug Evaluation, Preclin | 2015 |
Neuroprotective effects of 3-O-demethylswertipunicoside against MPTP-induced Parkinson's disease in vivo and its antioxidant properties in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biphenyl Comp | 2015 |
Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adaptive Immunity; Ana | 2016 |
Changes in plasma catecholamines levels as preclinical biomarkers in experimental models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Blood Chemical Analysis; Chromatography, High P | 2015 |
Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Combretum; Dopamine; Gene Expression Regulation; Homovanill | 2016 |
Physical exercise counteracts MPTP-induced changes in neural precursor cell proliferation in the hippocampus and restores spatial learning but not memory performance in the water maze.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Bromodeoxyuri | 2016 |
MPTP neurotoxicity is highly concordant between the sexes among BXD recombinant inbred mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2016 |
Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Dopamine; Homovanillic Acid; Locomotion; Mal | 2016 |
Effect of MPTP on mRNA expression of PGC-1α in mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopami | 2017 |
Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipyrine; Cyclooxygenase Inhibitors; Dopamine; Edaravone; | 2008 |
Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Cytoprotection; Dopamine; Drug Evaluation, | 2008 |
Significant effect of dimethylsulfoniopropionate on Parkinson's disease of senescence-accelerated mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Alzheimer Disea | 2008 |
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; CD11b Antigen; Chromatography, High Pressure Liq | 2009 |
Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Analysis of Variance; Animals; Blotting, Western; Chrom | 2009 |
Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Cell Death; Cell | 2009 |
Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain Chemistry; Cell Division; Chrom | 2010 |
Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Western; Dopamine; Dopamine Plasma Membrane Trans | 2009 |
Chronic administration with rotenone does not enhance MPTP neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain; Dopamine; Dopamine Agents; Male; M | 2010 |
Effects of hydroxysafflor yellow A in the attenuation of MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalase; Chalcone; Corpus Striatum; Dopamine; Glutathione; | 2010 |
The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antioxidants; Corpus Striatum; Diseas | 2010 |
Ameliorative and neuroprotective effect in MPTP model of Parkinson's disease by Zhen-Wu-Tang (ZWT), a traditional Chinese medicine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Cor | 2010 |
Selenium partially reverses the depletion of striatal dopamine and its metabolites in MPTP-treated C57BL mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Male; Mice; M | 2010 |
Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 2011 |
Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Weight; Brain-Derived Neurotrophic Factor; Caffeic Aci | 2011 |
The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; A | 2011 |
Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Age Factors; Aging; An | 2012 |
Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neuro | 2013 |
A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dependovirus; Dopamine; Erythropoietin; Ge | 2013 |
Consequences of manganese administration for striatal dopamine and motor behavior in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Drug Interacti | 2013 |
Dopamine and its metabolites in cathepsin D heterozygous mice before and after MPTP administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Cathepsin D; Corpus Striatum; Dopamine | 2013 |
Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Cocaine; Dihydrotestosterone; Dopamine; Do | 2002 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Chelating Age | 2003 |
Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-1 Rec | 2003 |
Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-Antagonists; Animals; Chromatography, High Pressure | 2003 |
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 2004 |
Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transpo | 2004 |
Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine Monophosphate; Animals; Brain; Brain Chemistry; Chromatogr | 2004 |
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzophenones; Brain; Corpus Striatum; Disease Models, Anim | 2004 |
Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Cell Communication; Dopamine; Glial | 2004 |
Reduced MPTP toxicity in noradrenaline transporter knockout mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Blotting, Western; Brain Chemistry; C | 2004 |
Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2005 |
Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Corpus Striatum; Dopamine; Enkephalins; Es | 2005 |
Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Anima | 2005 |
Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetates; Animals; Die | 2004 |
The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2006 |
Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Ataxia; Bromocriptine; Catalase; Corp | 2006 |
Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Biogenic Monoamines | 2007 |
Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Complement C3; Dopami | 2007 |
Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antibodies; Astrocytes; Behavior, Animal; Blotting, Western | 2008 |
Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2008 |
Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Animals, Newborn; Cell Count; Disease | 2008 |
Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Callithrix; Dopamine; Enkephalin, Methionine; Female | 1995 |
(+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Ditiocarb; Dizocilpine Maleate | 1994 |
Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Epidermal Growth Factor; Fibroblast Growth Factor | 1995 |
MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Dopamine; Homovanillic Acid; Male; Mice; Mice, Inbre | 1994 |
Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid | 1993 |
Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Carbachol; Corpus Striatum; Dopamine; Drug S | 1994 |
Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Biomarkers; Calbindin 1; Calbindins; | 1994 |
Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 1994 |
Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 1994 |
MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1994 |
1-Methyl-4-phenylpyridinium has greater neurotoxic effect after selenium deficiency than after vitamin E deficiency in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Weight; Dopamine; Eating; Free Radicals; Glutathione P | 1994 |
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1993 |
Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1993 |
LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Drug Resis | 1993 |
Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase B.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Cricetinae; Dopamine; Isoenzym | 1994 |
Effects of ageing on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxic effects on striatum and brainstem in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Antioxidants; Ascorbic Acid; Brain Stem; Corpus Stri | 1993 |
Age-related susceptibility to MPTP-induced neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Fluoresceins; Homovanillic Acid; | 1993 |
Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; Brain Chemistry; Callithrix; Chromatography, | 1993 |
Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Estradiol; Female; Levodopa; Mic | 1996 |
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Enz | 1996 |
Dopamine differentiation factors increase striatal dopaminergic function in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Fibroblast Grow | 1996 |
Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 1996 |
Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Carrier Proteins; Corpus Striatum; Do | 1997 |
Cognitive changes in mice following moderate MPTP exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-Agonists; Animals; Cerebral Cortex; Cognition; Corp | 1998 |
Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Male; Mice; M | 1998 |
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 1998 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Brain Chemistry; Ca | 1998 |
GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Metabolism; Dextroamphetamine; Dopamine; Dopamine Age | 1999 |
Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caspase 1; Corpus Striatum; Dopamine; Drug Resistance; Gene | 1999 |
Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catalase; Cor | 1999 |
Methamphetamine- and 1-methyl-4-phenyl- 1,2,3, 6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Temperature; Carrier Proteins; Dopamine; Dopamine Plas | 1999 |
Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1999 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Effect of MPTP on brain mitochondrial H2O2 and ATP production and on dopamine and DOPAC in the striatum.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Adenosine Triphosphate; Animals; Brain; | 1999 |
Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2000 |
Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 2000 |
Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Corpus Striatum; Dopamine; Dopamine Plasm | 2000 |
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Cell Count; Corpus Striatum; Disease Mode | 2000 |
DNA damage in brain mitochondria caused by aging and MPTP treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Aging; Animals; Brain Chemistry; DNA Damage; DNA, Mitoc | 2000 |
Profound astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic lesion by repeated MPTP administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; | 2001 |
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Corpus Striatum; Dopamine; Glutathione; Homovani | 2002 |
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Anesthesia, General; Animals; Benzhydryl Compounds; Central Nervous | 1992 |
MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cats; Caudate Nucleus; Dopamine; Female; | 1992 |
Investigation of the possible dopaminergic toxicity of 1-methyl-3-phenyl-1,2,3,6-tetrahydropyridine, an isomer to the neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 1991 |
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1991 |
The acute convulsant effect of MPTP is dependent on intracerebral MPP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 1991 |
Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Callit | 1991 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1990 |
Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Benzazepines; Brain; Dopamine; Homovanilli | 1989 |
Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Designer Drugs; Dopamine; Electroretinogra | 1989 |